|
|
Volumn 297, Issue 5589, 2002, Pages 1982-1984
|
|
After the gold rush: Gene firms reinvent themselves
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DRUG PRODUCTS;
INVESTMENTS;
SEQUENCE DATA;
GENES;
DNA;
DRUG;
GENOME;
BIOMEDICINE;
CRYSTALLOGRAPHY;
DNA SEQUENCE;
FACTUAL DATABASE;
GENE SEQUENCE;
GENE STRUCTURE;
GENETIC DISORDER;
GENOMICS;
HUMAN;
HUMAN GENOME;
INDUSTRY;
INVESTMENT;
MARKET;
MARKETING;
MEDICAL RESEARCH;
MONEY;
PRIORITY JOURNAL;
PROFIT;
SEQUENCE ANALYSIS;
SHORT SURVEY;
ACCESS TO INFORMATION;
ANIMAL;
ARTICLE;
BIOLOGY;
BIOTECHNOLOGY;
CHEMISTRY;
CLINICAL TRIAL;
DISEASE MODEL;
DRUG DESIGN;
DRUG INDUSTRY;
ECONOMICS;
GENETIC DATABASE;
MOUSE;
ORGANIZATION AND MANAGEMENT;
ACCESS TO INFORMATION;
ANIMALS;
BIOTECHNOLOGY;
CHEMISTRY, PHARMACEUTICAL;
CLINICAL TRIALS;
COMPUTATIONAL BIOLOGY;
DATABASES, GENETIC;
DISEASE MODELS, ANIMAL;
DRUG DESIGN;
DRUG INDUSTRY;
GENOMICS;
HUMANS;
INVESTMENTS;
MICE;
PHARMACEUTICAL PREPARATIONS;
PRIVATE SECTOR;
PUBLIC SECTOR;
|
|
EID: 0037144376
PISSN: 00368075
EISSN: None
Source Type: Journal
DOI: 10.1126/science.297.5589.1982 Document Type: Short Survey |
|
Times cited : (9)
|
|
References (0)
|